

Methylnaltrexone for the treatment of opioid-induced bowel dysfunction in advanced illness or palliative care

<http://guidance.nice.org.uk/TA/Wave18/24>

Dear Consultees and commentators,

The manufacturer has identified the need for further data to enable NICE to undertake a robust appraisal of methylnaltrexone. Therefore they have informed us that they feel that it is not possible to make a submission at this time. There are a number of studies currently ongoing and the manufacturer believes that they will be in a position to submit in early/mid 2010.

Consultees who have already submitted will have an opportunity to re-submit, if they wish.

We will send a further email when we have confirmed the dates.

Best wishes,

Jeremy

Jeremy Powell

Technology Appraisal Project Manager

National Institute for Health and Clinical Excellence

MidCity Place | 71 High Holborn | London WC1V 6NA | United Kingdom

Tel: 44 (0)20 7045 2248 | Fax: 44 (0)20 7061 9830